Halozyme Therapeutics, Inc.
HALO- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001159036
In the last 90 days, Halozyme Therapeutics, Inc. insiders filed 0 open-market purchases and 6 sales; 673 institutions reported holding it in 13F filings for Q2 2026, worth $9.62B in total; no superinvestor holds it.
13F holders, Q2 2026
Institutional positions in Halozyme Therapeutics, Inc. as of Jun 30, 2026. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 673
- +43 vs. Q1 2026
- Shares held
- 123.3M
- +4.08M (+3.4%) vs. Q1 2026
- Total value
- $9.62B
- +$1.91B (+24.9%) vs. Q1 2026
- New holders
- 109
- 269 more added
- Sold out
- 66
- 207 more reduced
7 institutions that held it in Q1 2026 haven't filed for Q2 2026 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q1 2026: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting HALO on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 673 | $9.62B |
| Q1 2026 | 637 | $7.79B |
| Q4 2025 | 619 | $8.29B |
| Q3 2025 | 604 | $8.75B |
| Q2 2025 | 552 | $6.05B |
| Q1 2025 | 550 | $7.72B |
| Q4 2024 | 509 | $5.86B |
| Q3 2024 | 510 | $7.17B |
| Q2 2024 | 460 | $6.40B |
| Q1 2024 | 413 | $5.03B |
| Q4 2023 | 411 | $4.62B |
| Q3 2023 | 390 | $4.71B |
| Q2 2023 | 370 | $4.45B |
| Q1 2023 | 387 | $4.77B |
| Q4 2022 | 423 | $7.35B |
| Q3 2022 | 357 | $5.21B |
| Q2 2022 | 368 | $5.65B |
| Q1 2022 | 316 | $5.12B |
| Q4 2021 | 326 | $5.21B |
| Q3 2021 | 326 | $5.29B |
| Q2 2021 | 315 | $5.89B |
| Q1 2021 | 337 | $5.53B |
Institutions, Q2 2026
Shares, value and share of portfolio for each institution holding Halozyme Therapeutics, Inc.; share changes are against Q1 2026.